Condition: Orthopedics · Traumatology · Sponsor: AUVA Traumazentrum Vienna Site UKH Meidling
This is a prospective, single-center, placebo-controlled, non-comparative, phase II study to evaluate the influence of an adjuvant, intravenous therapy with zoledronic acid (single dose) on healing after arthroscopic repair of chronic rotator cuff tears. The study including its financial support was approved by the medical director of the General Accident Insurance Institution (AUVA) , Dr. Roland Frank. Hypothesis to prove: Adjuvant intravenous therapy with zoledronic acid does improve tendon healing after arthroscopic reconstruction of chronic rotator cuff tears compared to a control group without adjuvant therapy with zoledronic acid.,
This description comes directly from the study's public registry record.
Jakob Schanda, DDr. · +435939345201 · jakob.schanda@auva.at
Ortrun Neuper, MSc. · +436764543334 · oneuper@trauma.lbg.ac.at
Always discuss trial participation with your own doctor first.
| Jakob Schanda | Vienna, Austria | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05677152